Floatz logo

Chir-258

Melanoma

Novartis PharmaceuticalsPhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
65/ 100

Competitive context

329 Active assets in the Melanoma cohort.

Asset / SponsorPhaseRating
DACARBAZINE
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 3BB
Cyclophosphamide
Primmune Therapeutics, Inc.
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Epirubicin
Primmune Therapeutics, Inc.
Phase 4BB
Pembrolizumab
Biocon Biologics UK PLC
Phase 4BB

View all 50 →

Same molecule, other indications

Chir-258 is also rated in:

NeoplasmsDormant
B
Indicative ·
57 / 100
View asset →
Stage III Pancreatic CancerDormant
CCC
Indicative ·
54 / 100
View asset →
Breast CancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →